+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Monoclonal Antibodies (MAbS) Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • ID: 5319143
  • Report
  • April 2021
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • Abbott Laboratories
  • Agensys
  • Amgen
  • Celldex Therapeutics
  • Hoffman Roche Ltd
  • Norvatis AG
Monoclonal Antibodies (MAbS) Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides strategists, marketers and senior management with the critical information they need to assess the global monoclonal antibodies (mabs) market as it emerges from the COVID-19 shut down.



Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:

Where is the largest and fastest growing market for the monoclonal antibodies (mabs)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Monoclonal Antibodies (MAbS) Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:
1) By Source: Murine; Chimeric; Humanized; Human
2) By Application: Anti-Cancer; Immunological; Anti-Infective Monoclonal Antibodies (MAbs); Neuropharmacological; Cardiovascular And Cerebrovascular; Others
3) By End Users: Hospitals; Private Clinics; Research Institute

Companies Mentioned: Johnson & Johnson; Merck; AbbVie; Amgen; Glaxosmithkline plc

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Frequently Asked Questions about the Global Monoclonal Antibodies (Mabs) Market

What is the estimated value of the Global Monoclonal Antibodies (Mabs) Market?

The Global Monoclonal Antibodies (Mabs) Market was estimated to be valued at €114.40 billion in 2021.

What is the growth rate of the Global Monoclonal Antibodies (Mabs) Market?

The growth rate of the Global Monoclonal Antibodies (Mabs) Market is 11.9%, with an estimated value of €179.60 billion by 2025.

What is the forecasted size of the Global Monoclonal Antibodies (Mabs) Market?

The Global Monoclonal Antibodies (Mabs) Market is estimated to be worth €179.60 billion by 2025.

Who are the key companies in the Global Monoclonal Antibodies (Mabs) Market?

Key companies in the Global Monoclonal Antibodies (Mabs) Market include Johnson & Johnson, Merck, AbbVie, Amgen, Glaxosmithkline plc, Norvatis AG, Pfizer Inc, Thermofischer Scientific and Bristol.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Agensys
  • Amgen
  • Celldex Therapeutics
  • Hoffman Roche Ltd
  • Norvatis AG
1. Executive Summary

2. Monoclonal Antibodies (MAbS) Market Characteristics

3. Monoclonal Antibodies (MAbS) Market Trends And Strategies

4. Impact Of COVID-19 on Monoclonal Antibodies (MAbS)

5. Monoclonal Antibodies (MAbS) Market Size And Growth
5.1. Global Monoclonal Antibodies (MAbS) Historic Market, 2015-2020, $ Billion
5.1.1. Drivers of the Market
5.1.2. Restraints on The Market
5.2. Global Monoclonal Antibodies (MAbS) Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers of the Market
5.2.2. Restraints on the Market

6. Monoclonal Antibodies (MAbS) Market Segmentation
6.1. Global Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Murine
  • Chimeric
  • Humanized
  • Human
6.2. Global Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Anti-Cancer
  • Immunological
  • Anti-Infective Monoclonal Antibodies (Mabs)
  • Neuropharmacological
  • Cardiovascular And Cerebrovascular
  • Others
6.3. Global Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospitals
  • Private Clinics
  • Research Institute
7. Monoclonal Antibodies (MAbS) Market Regional And Country Analysis
7.1. Global Monoclonal Antibodies (MAbS) Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Monoclonal Antibodies (MAbS) Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

8. Asia-Pacific Monoclonal Antibodies (MAbS) Market
8.1. Asia-Pacific Monoclonal Antibodies (MAbS) Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.4. Asia-Pacific Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

9. China Monoclonal Antibodies (MAbS) Market
9.1. China Monoclonal Antibodies (MAbS) Market Overview
9.2. China Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.4. China Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

10. India Monoclonal Antibodies (MAbS) Market
10.1. India Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.3. India Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

11. Japan Monoclonal Antibodies (MAbS) Market
11.1. Japan Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.3. Japan Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Australia Monoclonal Antibodies (MAbS) Market
12.1. Australia Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.3. Australia Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

13. Indonesia Monoclonal Antibodies (MAbS) Market
13.1. Indonesia Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.3. Indonesia Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

14. South Korea Monoclonal Antibodies (MAbS) Market
14.1. South Korea Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.3. South Korea Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

15. Western Europe Monoclonal Antibodies (MAbS) Market
15.1. Western Europe Monoclonal Antibodies (MAbS) Market Overview
15.2. Western Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.4. Western Europe Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

16. UK Monoclonal Antibodies (MAbS) Market
16.1. UK Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.3. UK Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

17. Germany Monoclonal Antibodies (MAbS) Market
17.1. Germany Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.3. Germany Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

18. France Monoclonal Antibodies (MAbS) Market
18.5. France Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.6. France Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.7. France Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

19. Eastern Europe Monoclonal Antibodies (MAbS) Market
19.1. Eastern Europe Monoclonal Antibodies (MAbS) Market Overview
19.2. Eastern Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.4. Eastern Europe Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

20. Russia Monoclonal Antibodies (MAbS) Market
20.1. Russia Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.3. Russia Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

21. North America Monoclonal Antibodies (MAbS) Market
21.1. North America Monoclonal Antibodies (MAbS) Market Overview
21.2. North America Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.4. North America Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

22. USA Monoclonal Antibodies (MAbS) Market
22.1. USA Monoclonal Antibodies (MAbS) Market Overview
22.2. USA Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.4. USA Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

23. South America Monoclonal Antibodies (MAbS) Market
23.1. South America Monoclonal Antibodies (MAbS) Market Overview
23.2. South America Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.4. South America Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

24. Brazil Monoclonal Antibodies (MAbS) Market
24.1. Brazil Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.3. Brazil Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

25. Middle East Monoclonal Antibodies (MAbS) Market
25.1. Middle East Monoclonal Antibodies (MAbS) Market Overview
25.2. Middle East Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.4. Middle East Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

26. Africa Monoclonal Antibodies (MAbS) Market
26.1. Africa Monoclonal Antibodies (MAbS) Market Overview
26.2. Africa Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.4. Africa Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

27. Monoclonal Antibodies (MAbS) Market Competitive Landscape And Company Profiles
27.1. Monoclonal Antibodies (MAbS) Market Competitive Landscape
27.2. Monoclonal Antibodies (MAbS) Market Company Profiles
27.2.1. Johnson & Johnson
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Merck
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. AbbVie
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Amgen
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Glaxosmithkline plc
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance

28. Monoclonal Antibodies (MAbS) Pipeline Analysis

29. Key Mergers And Acquisitions In The Monoclonal Antibodies (MAbS) Market

30. Monoclonal Antibodies (MAbS) Market Future Outlook and Potential Analysis

31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Agensys
  • Amgen
  • Celldex Therapeutics
  • Hoffman Roche Ltd
  • Norvatis AG
Major players in the monoclonal antibodies (MABS) market are Johnson & Johnson, Merck, AbbVie, Amgen, and GlaxoSmithKline plc.

The global monoclonal antibodies (mabs) market is expected to grow from $106.87 billion in 2020 to $114.43 billion in 2021 at a compound annual growth rate (CAGR) of 7.1%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $179.56 billion in 2025 at a CAGR of 11.9%.

The monoclonal antibodies (MABS) market consists of sales of monoclonal antibodies and related services. Monoclonal antibodies are used to enhance and suppress the immune response in various medical conditions and to treat various diseases such as cancer, cardiovascular and cerebrovascular diseases. This industry includes establishments that produce anti-cancer monoclonal antibodies to prevent metastasis by reducing cell proliferation, immunological monoclonal anti-bodies, neuropharmacological monoclonal anti-bodies, anti-infective monoclonal antibodies (MAbs), and other MAbs for human beings and animals.

The monoclonal antibodies market has been witnessing multiple strategic initiatives in recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden products and services. Strategic collaborations or acquisitions and partnership agreements help vendors expand their existing product portfolio and geographical reach. For instance, In February 2019, AbCellera and Novartis enter into a multi-target partnership to create an antibody-drug discovery platform and technology for treating clinically-relevant and neurodegenerative diseases. Furthermore, AbCellera collaborated with GlaxoSmithKline (GSK), a pharmaceutical company, for the discovery of monoclonal antibodies against an undisclosed membrane protein target. Merck completed the acquisition of Sigma-Aldrich Corp., a leading life science company. Post this acquisition, Merck has more than 50,000 employees, 72 manufacturing sites, and a presence in 67 countries worldwide. Companies in the industry are increasingly realigning their portfolios and pursue profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favorable interest rates globally.

The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services, in the USA regulating the monoclonal antibodies and pharmaceutical drugs market. Increasing product launches and regulatory support for the treatment of rare diseases by USFDA is expected to support the monoclonal antibody therapeutics market growth. For instance, the U.S. Food and Drug Administration (FDA) granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.), a human monoclonal antibody, for the treatment of a rare disease, metastatic Merkel cell carcinoma (MCC). Similarly, the U.S FDA granted accelerated approval to immunotherapy product- TECENTRIQ (atezolizumab), a humanized, engineered monoclonal antibody, for the treatment of people with locally-advanced or metastatic urothelial carcinoma (mUC).

The Increasing prevalence of cost-efficient biosimilar monoclonal antibodies are driving the monoclonal antibodies market growth. The biosimilar aim is to curb the increasing healthcare cost and handle economic pressure from the patient pod and governments to reduce the cost of medication and increase access to treatment. Biosimilar is the pharmaceuticals that are developed to have similar properties to a biologic drug that has already been approved. A biosimilar monoclonal antibody costs 20%-25% lesser than the originator biologic drug. The number of clinical trials for a biosimilar is comparatively lesser than that of the original biologic drug and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry.

Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to have a negative impact on the revenues of the monoclonal antibody drugs market. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, the revenue of US retail sales of homeopathic and herbal remedies was around $7.5 billion. These less expensive alternatives increase competitiveness for the biologics market putting downward pressure and limiting the demand for monoclonal antibody drugs.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Johnson & Johnson
  • Merck
  • AbbVie
  • Amgen
  • Glaxosmithkline plc
  • Norvatis AG
  • Pfizer Inc
  • Thermofischer Scientific
  • Elililly and Company
  • Bristol-Myers Squibb
  • Hoffman Roche Ltd
  • Sanofi
  • Abbott Laboratories
  • Mylan N.V
  • Novo Nordisk A/S
  • Daiichi Sankyo Company ltd.
  • Seattle genetics
  • Teva pharmaceutical industries
  • Shanghi Junsi bioscience ltd
  • GenScript
  • Sigma-Aldrich Co. LLC
  • AbGenomics
  • ADC Therapeutics
  • Agensys
  • Alexion Pharmaceuticals
  • ALMAC Group
  • Ambrx
  • Astellas Pharma
  • Celgene
  • Celldex Therapeutics
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll